Navigation Links
FDA Will Wait for Trial Results on Vytorin
Date:1/25/2008

ce in risk of heart attack or stroke between the two treatments.

Jenkins said another ongoing trial will evaluate the effect of Vytorin compared with Zocor on heart disease and stroke. Results from this trial will be available in 2011, he said.

Merck/Schering-Plough Pharmaceuticals, the makers of Zetia and Vytorin, have been criticized for not releasing the Enhance test results earlier.

"While the Enhance trial was time-consuming and took longer than originally anticipated to complete, our companies acted with integrity and good faith in connection with the trial," Thomas Koestler, president of the Schering-Plough Research Institute, said in a prepared statement released Friday.

Dr. Harlan M. Krumholz, a professor of medicine at Yale University School of Medicine, said the FDA is right to wait until all the results from the Enhance trial are in. But in the meantime, he said, Vytorin and Zetia should be limited to patients who can't tolerate cholesterol-lowering drugs called statins, such as Lipitor.

"We have enough information from Enhance to say it is not providing much evidence that this drug is delaying the progression of atherosclerosis," he said. "It raises uncertainty whether this drug produces benefits for actual patients."

"This [Vytorin] is really a second-line drug," Krumholz said. "We really should be guided by evidence, not marketing, and the evidence is really strong for statins. If lifestyles aren't sufficient to lower cholesterol, the next place they should go is statins. Only after those have failed should you go to the next step," he added, referring to Vytorin.

More information

For more information on lowering cholesterol, visit the American Heart Association.



SOURCES: Harlan M. Krumholz, M.D., professor, medicine, Yale University Schoo
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Anti-Clotting Drug Trial Shortened by Bleeding Problems
2. Malaria Vaccine Shows Promise in Small Trial
3. Debate over safety of gene therapy trials focuses on issue of informed consent
4. Immunosyn Announces the Successful Completion of First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
6. Black Americans Still Wary of Clinical Trials
7. Vaccines for Ovarian and Breast Cancer in Early Trials
8. Industrial Solvent May Increase Risk for Parkinsonism
9. Industrial Solvent May Increase Risk for Parkinsons Disease
10. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
11. New study: US ranks last among other industrialized nations on preventable deaths
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Will Wait for Trial Results on Vytorin
(Date:8/30/2014)... 30, 2014 According to Bloomberg ... that requires Takeda Pharmaceutical Co. and Eli Lilly & ... claims that the drugmakers concealed information about a risk ... The case, Allen v. Takeda Pharmaceuticals North America Inc. ... District of Louisiana (Lafayette).* , According to Bloomberg, Takeda ...
(Date:8/30/2014)... Recently, Skmen.com, a well-known clothing manufacturer, has ... . Before the middle of September, all the company’s ... from 15 to 30 percent off. , As ... outfits are carefully made and come with quality guarantees. ... wearers. Skmen.com is popular for its fashionable, high quality ...
(Date:8/30/2014)... CA (PRWEB) August 30, 2014 Ticket Down ... vs. Chile exhibition match next Saturday at Levi's Stadium. ... for diehard soccer fans in the United States due to the ... in just about every major city. Many of these games ... in Brazil this past summer. , Levi’s Stadium is a brand ...
(Date:8/30/2014)... 2014 Information supplied by insurance companies ... better prices to consumers in 2014. A group of ... when using the open system for adults at ... to use this year can help the average person ... location and not from medical histories. The finder tool ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Mexico vs. Chile Tickets at Levi's Stadium in Santa Clara, CA: TicketDown.com Offers Promo Code for Mexico vs. Chile Exhibition Game on September 6th 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:United Theological Seminary Announces First Fully Online Degree 2
... finds increased risk of heart failure , , MONDAY, Dec. 22 (HealthDay ... inactivity increased the risk of heart failure in a major study ... overweight men who are not obese have an increase in heart ... on the finding in the Dec. 23 issue of Circulation ...
... December 22, 2008 The Women,s Heart Health Initiative ... creation of a new fellowship dedicated to gender-specific research ... heart disease in women. The announcement will take place ... , "Women face unique challenges to successful diagnosis ...
... almost 4 times the odds, study says , , MONDAY, ... increases a pregnant woman,s likelihood of having a Caesarean ... Boston University School of Medicine and Boston Medical Center ... pregnant women and Caesarean section. Of the 253 women ...
... of suffering from overweight and obesity. This is the result ... starting school. Elisabeth Weber and her coauthors present the results ... ( Dtsch Arztbl Int 2008; 105 [51-52]: 883-9). The ... of the children, but also their mother tongue. Their parents ...
... switch ,on, in those with lupus, rheumatoid arthritis , , ... potential autoimmune disease-causing cells, but these cells stay in ... cells that attack the body cause autoimmune diseases such ... cells in healthy adults are true precursors of the ...
... the Support of Long Term Care elects healthcare software expert Eric Christ ... ... -- The National Association for the Support of Long Term Care (NASL) ... the president of Patient Placement Systems , part of the Jackson ...
Cached Medicine News:Health News:Even a Little Overweight, Inactivity Hurts the Heart 2Health News:Eric Christ of Long-Term Care Software Leader Patient Placement Systems' Elected to NASL Board of Directors 2
(Date:8/29/2014)... 29, 2014 Diseases largely eradicated in ... are returning. Measles was declared eliminated in 2000, yet ... of August 15—the highest incidence in 20 years. In ... declared whooping cough a problem of "epidemic proportions." ... and dying from these preventable diseases—in part because some ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)... PASO ROBLES, Calif. , Aug. 29, 2014 /PRNewswire/ ... launch of its new website design . The ... an overhaul that showcases the company,s new services and ... By implementing a new streamlined design, viewers can ... deliver metrics for health care practices and create a ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2
... CHAPEL HILL, N.C., Nov. 21, 2011  In today,s payer-driven ... success of a new pharmaceutical product. However, sustaining commercial ... and processes that will increase market share after the ... half of practices to manage the challenges of the ...
... N.J., Nov. 21, 2011  Watson Pharmaceuticals, Inc. (NYSE: ... today that Paul Bisaro, Watson,s President and Chief Executive ... Company,s business at the 2011 Piper Jaffray Health Care ... EST at the New York Palace Hotel in New ...
Cached Medicine Technology:Managed Care Pull-Through Programs Target Physicians, Boost Market Share 2
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... Bio-Dot SF (slot format) microfiltration units provide ... nucleic acid in solution onto nitrocellulose or ... accommodated by using interchangeable templates to form ... format Bio-Dot SF apparatus. Each is available ...
... The Bio-Dot and Bio-Dot SF (slot ... for binding protein or nucleic acid in ... experimental protocols can be accommodated by using ... apparatus or 48-well slot format Bio-Dot SF ...
Medicine Products: